Welcome to the e-CCO Library!

OP20 The gut microbiota during biological therapy for inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Caenepeel1, S. Viera-Silva2, B. Verstockt3, K. Machiels3, N.A. Davani3, J. Sabino3,4, M. Ferrante3,4, J. Raes2, S. Vermeire3,4

Created: Thursday, 30 January 2020, 10:12 AM
OP20: Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Lewis*1, R. Jeffrey1, T. Kumagai1, C. J. Hawkey2, M. M. Clark2, M. Allez3, J. Satsangi4, G. Rogler5, A. Silver1, J. O. Lindsay6

Created: Friday, 22 February 2019, 9:41 AM
OP20: Perianal fistulas are characterised by expansion of interleukin-22 producing invariant natural killer T-cells and CD4+ T-cells which drive dysregulation of the extracellular matrix
Year: 2022
Source: ECCO'22
Authors: Constable, L.(1,2);Iqbal, N.(3,4);Cozzetto, D.(1);Hart , A.(3,4);Tozer, P.(3,4);Powell, N.(1);
Created: Friday, 11 February 2022, 3:52 PM
OP20: Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemIBD study
Year: 2021
Source: ECCO'21 Virtual
Authors: Chaparro, M.(1);Garre, A.(1);Núñez Ortiz , A.(2);Diz-Lois Palomares, M.T.(3);Rodríguez, C.(4);Riestra, S.(5);Vela, M.(6); Benítez, J.M.(7);Fernández Salgado, E.(8);Sánchez Rodríguez, E.(9);Hernández, V.(10);Ferreiro-Iglesias, R.(11);Ponferrada Díaz, Á.(12);Barrio, J.(13); Huguet, J.M.(14);Arias, L.(15);Martín-Arranz, M.D.(16);Calvet, X.(17);Ginard, D.(18);Alonso-Abreu, I.(19);Fernández-Salazar, L.(20);Varela Trastoy, P.(21);Rivero, M.(22);Vera-Mendoza, I.(23);Vega, P.(24);Navarro, P.(25);Sierra, M.(26); Cabriada, J.L.(27);Aguas, M.(28);Vicente, R.(29);Navarro-Llavat, M.(30);Echarri, A.(31);Gomollón, F.(32);Guerra del Río, E.(33);Casanova, M.J.(1);Spicakova, K.(34);Ortiz de Zarate, J.(35);Alonso-Galán, H.(36);Barreiro-de Acosta, M.(11);Gisbert, J.P.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
OP20: The effects of upadacitinib on ulcerative colitis symptom resolution and fatigue normalization in patients with moderately to severely active ulcerative colitis: Phase 3 U-ACHIEVE and U-ACCOMPLISH results
Year: 2023
Source: ECCO’23 Copenhagen
Authors: D'Haens, G.(1)*;Tran, J.(2,3);Danese, S.(4);Rubin, D.T.(5);Aoyama, N.(6);Lügering, A.(7);Klaff, J.(3);Xuan, S.(3);Ilo, D.(3);Sanchez Gonzalez, Y.(3);Panes, J.(8);
Created: Friday, 14 July 2023, 10:43 AM
OP21 Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Nice1, N. Chanchlani2, H. Green2, C. Bewshea2, N. Kennedy2, T. Ahmad2, J. Goodhand2, T. McDonald1, M. Perry1

Created: Thursday, 30 January 2020, 10:12 AM
OP21: ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Vermeire1, X. Hébuterne2, P. Napora3, M. Wisniewska-Jarosinska4, G. Kiss5, A. Bourreille6, Z. Przemysław7, J. Nitcheu8, P. Gineste8, J-M. Steens*8, H. Ehrlich8

Created: Friday, 22 February 2019, 9:41 AM
OP21: COVID-19 morbidity/mortality and vaccination against SARS-CoV-2 in patients with Inflammatory Bowel Disease in Poland: Nationwide Data
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Kucha, P.(1,2)*;Walkiewicz, D.(3);Wieszczy, P.(2,4);Reguła, J.(1,2);Zagórowicz, E.(1,2);
Created: Friday, 14 July 2023, 10:43 AM
OP21: COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab
Year: 2022
Source: ECCO'22
Authors: Alexander, J.(1,2);Kennedy, N.(3,4);Ibraheim, H.(1,2);Anandabaskaran, S.(1,5);Saifuddin, A.(1,5);Castro Seoane, R.(1);Liu, Z.(1);Nice, R.(4,6);Bewshea, C.(4);D'Mello, A.(7);Constable, L.(1);Jones, G.R.(8,9);Balarajah, S.(1,2);Fiorentino, F.(10);Sebastian, S.(11,12);Irving, P.M.(13,14);Hicks, L.(1,2);Williams, H.(1,2);Kent, A.(15);Linger, R.(16);King, R.(16);Parkes, M.(16,17);Kok, K.(18);Patel, K.(19);Altmann, D.(20);Boyton, R.(21);Goodhand, J.(3,4);Hart, A.(5);Lees, C.(8,9);Ahmad, T.(3,4);Powell, N.(1,2);
Created: Friday, 11 February 2022, 3:52 PM
OP21: Predictive value of Milan Ultrasound Criteria in Ulcerative Colitis: A prospective observational cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Allocca, M.(1);Dell’Avalle, C.(2);Furfaro, F.(2);Craviotto, V.(2);Zilli, A.(2);D'Amico, F.(2);Peyrin-Biroulet, L.(3);Fiorino, G.(1);Danese, S.(1)
Created: Wednesday, 2 June 2021, 4:12 PM
OP22 Crohn’s disease exclusion diet reduces bacterial dysbiosis towards healthy controls in paediatric Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Van Limbergen1, K. Dunn2, E. Wine3, R. Sigall Boneh4, J. Bielawski2, A. Levine4

Created: Thursday, 30 January 2020, 10:12 AM
OP22: Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients
Year: 2022
Source: ECCO'22
Authors: Lin, S.(1,2);Kennedy, N.A.(1,2);Saifuddin, A.(3,4);Muñoz Sandoval, D.(5);Reynolds, C.J.(5);Seoane, R.C.(6);Kottoor, S.H.(4);Pieper, F.P.(5);Lin, K.M.(5);Butler, D.K.(5);Chanchlani, N.(1,2);Nice, R.(2,7);Chee, D.(1,2);Bewshea, C.(2);Janjua, M.(1,2);McDonald, T.J.(7);Sebastian, S.(8,9);Alexander, J.L.(4,10);Constable, L.(4);Lee, J.C.(11,12,13);Murray, C.D.(11);Hart, A.L.(3);Irving, P.M.(14,15);Jones, G.R.(16,17);Kok, K.B.(18,19);Lamb, C.A.(20,21);Lees, C.W.(16,22);Altmann, D.M.(6);Boyton, R.J.(5,23);Goodhand, J.R.(1,2);Powell, N.(4,10);Ahmad, T.(1,2); CLARITY IBD
Created: Friday, 11 February 2022, 3:52 PM
OP22: Factors independently associated with fatigue in IBD: Results from the baseline dataset of the PREdiCCt study
Year: 2021
Source: ECCO'21 Virtual
Authors: Derikx, L.(1,2);Siakavellas, S.(2);Derr, L.(2);Williams, L.(2);Nikolas, P.(2);Jenkinson, P.(2);Lucaciu, L.(2);Constantine-Cooke, N.(3);Covil, K.(2);Murdoch, L.(2);Jones, G.R.(2,4);Lees, C.(2,5)
Created: Wednesday, 2 June 2021, 4:12 PM
OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Barnhoorn*1, L. Plug1, E. Muller - de Jonge1, E. Bos2, A. van der Meulen - de Jong1, H. Verspaget1, L. Hawinkels1

Created: Friday, 22 February 2019, 9:41 AM
OP22: The risk of cancer in pediatric-onset immune-mediated inflammatory diseases – a nationwide Danish study from 1980-2018.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ehrström, A.(1)*;Jansson, S.(1);Malham, M.(1);Wewer, V.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Vermeire1, W. Sandborn2, F. Baert3, S. Danese4, T. Kobayashi5, E.V. Loftus Jr6, S. Bhatia7, K. Kisfalvi8, M. Rosario9, W. Zhang10, G. D’Haens11

Created: Thursday, 30 January 2020, 10:12 AM
OP23: Asymptomatic inflammatory bowel disease diagnosed during the colorectal cancer population screening in Catalonia
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Brunet, E.(1,2)*;Selva, A.(3,4);Bas-Cutrina, F.(5);Brujats, A.(6,7);Caballol, B.(8);Gomez, B.(9);Gonzalez, C.(7);Busquets, D.(10);Monfort, D.(11);Vera, D.P.(12);Maristany, E.(13);Cirera, G.(14);Torres, G.(15);Castro-Poceiro, J.(16);Lopez, J.(17);Gonzalez-Gonzalez, L.(18);Marquez-Mosquera, L.(19);Gallach, M.(20);Esteve, M.(21);Tremosa, G.(22);Torra, S.(23);Robles, V.(24);Rodríguez-Lago, I.(25);Calvet, X.(2,26,27);
Created: Friday, 14 July 2023, 10:43 AM
OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis in various animal models
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Shin*1, N. Ha1, D. Bae1, D-h. Suh1, J-y. Baek1, J. H. Jun1, Y. J. Lee1, Y. I. Choi1, K. H. Ryu1, G. S. Youn2, J. Park2, S-M. Lee3, S-k. Seo3, J. W. Lee4, J. S. Kim4,5

Created: Friday, 22 February 2019, 9:41 AM
OP23: Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study
Year: 2021
Source: ECCO'21 Virtual
Authors: Vermeire, S.(1);Danese, S.(2);Zhou, W.(3);Pangan, A.(3);Greenbloom, S.(4);D'Haens, G.(5);Panes, J.(6);Juillerat, P.(7);Lindsay, J.O.(8);Loftus Jr, E.V.(9);Sandborn, W.J.(10);Reinisch, W.(11);Sanchez Gonzalez, Y.(3);Huang, B.(3);Xie, W.(3);Liu, J.(3);Weinreich, M.A.(3);Panaccione, R.(12)
Created: Wednesday, 2 June 2021, 4:12 PM
OP23: The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12
Year: 2022
Source: ECCO'22
Authors: Dignass, A.(1);Rubin, D.(2);Bressler, B.(3);Huang, K.H.(4);Shipitofsky, N.(4);Germinaro, M.(4);Zhang, H.(4);Johanns, J.(4);Feagan, B.(5);Sandborn, W.(6);Sands, B.(7);Hisamatsu, T.(8);Lichtenstein, G.(9);Panes, J.(10);Allegretti , J.(11); QUASAR Investigators
Created: Friday, 11 February 2022, 3:52 PM